Research peptide
Vial · 10, 20 or 40 mg
Choose your vial format: 10 mg, 20 mg or 40 mg. Each unit contains one vial.
1 vial × AED 599 · Total AED 599
One vial containing 20 mg of Retatrutide. The most popular format in the range.
Worldwide delivery in 3–5 business days. Free delivery with the 40 mg vial. Transport conditions must be confirmed before ordering.
Payment requires a secure payment service. No payments are collected here.
Check the laboratory identity and batch number on the certificate of analysis.
The compound
Retatrutide (LY-3437943) is an investigational triple receptor agonist peptide. It activates three metabolic receptors: GLP-1 (glucagon-like peptide 1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon.
Its combined receptor activity is being investigated in controlled research programmes. Published studies describe the investigational compound; they do not validate the identity or performance of a separately supplied research product.
2023 · Phase 2 · Peer-reviewed
In the Phase 2 trial published in The New England Journal of Medicine, the 12 mg retatrutide group had a least-squares mean body-weight change of −24.2% at 48 weeks, compared with −2.1% with placebo.
Read the NEJM publication (opens in a new tab)May 2026 · Phase 3 · Sponsor-reported
Lilly’s May 2026 topline announcement reported average weight changes at 80 weeks of −19.0% with 4 mg, −25.9% with 9 mg, and −28.3% with 12 mg, compared with −2.2% with placebo.
In a prespecified 104-week extension among participants with baseline BMI ≥35, the 12 mg group reached an average −30.3% weight change. These figures were announced by the sponsor as topline results; the study groups and quantities are not instructions for use.
Read Lilly’s trial announcement (opens in a new tab)Format, documentation & delivery
Choose a vial containing 10 mg, 20 mg or 40 mg of Retatrutide to match the total quantity required for your in vitro research. Each unit contains one vial in the selected format.
Review the measured purity in the certificate for the exact batch supplied. Analytical panels may include identity, HPLC purity, endotoxin, heavy metals and net peptide content, where applicable. Each result should identify its laboratory and method.
Review batch documentationCheck that the analytical report matches the vial format and the exact batch you receive.
Keep the vial with its original packaging and batch information. Cold-chain insulated packaging supports the +2 to +8°C transport range. Keep the packaging and product information together, and follow the storage conditions specified for the batch.
Confirm the supplied accessories and batch documents before ordering.
Worldwide delivery in 3–5 business days.
Cold-chain shipping maintains the +2 to +8°C range during delivery.
A traceable product links its packaging, batch reference and analytical documentation. Review the source, packing details and report reference for the actual batch before ordering.
No Swiss Peptide batch report is currently published on this page. Reports issued for another supplier or batch cannot verify this product.
Check documentation availabilityThree receptor pathways
Retatrutide activates GLP-1, GIP and glucagon receptors. Laboratory studies investigate how these three pathways contribute to its pharmacology. The descriptions below concern receptor biology and published research, not established effects of this vial.
GLP-1 receptor signalling is involved in appetite regulation and glucose-dependent insulin secretion. GLP-1 receptor agonists can also slow gastric emptying. This receptor is targeted by semaglutide and is one of the two receptor targets of tirzepatide.
GIP is an incretin pathway involved in glucose-dependent insulin secretion. Retatrutide and tirzepatide both activate the GIP receptor alongside GLP-1 receptors; retatrutide additionally activates the glucagon receptor.
Glucagon-receptor activation is the third component of retatrutide’s receptor profile. In the original discovery study, this component increased energy expenditure in obese mice. That preclinical finding does not establish the same independent effect in humans or demonstrate the performance of a separately supplied product.
Understanding the differences
A reference to receptor targets and selected published trials. The studies below used different populations, durations and statistical analyses; their results are not a head-to-head comparison or a prediction of individual outcomes.
Swipe horizontally to compare all three compounds.
| Research characteristic | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Receptor targets | GLP-1 + GIP + glucagon | GLP-1 + GIP | GLP-1 |
| Mechanism | Triple receptor agonist | Dual receptor agonist | Single receptor agonist |
| Selected published trial | Phase 2 · 48 weeksNEJM · 2023 (opens in a new tab) | SURMOUNT-1 · 72 weeksNEJM · 2022 (opens in a new tab) | STEP 1 · 68 weeksNEJM · 2021 (opens in a new tab) |
| Mean body-weight change in the cited study group | −24.2%12 mg study group; −2.1% with placebo. | −22.5%15 mg group, efficacy estimand; −2.4% with placebo. The treatment-regimen estimand was −20.9% versus −3.1%. | −14.9%2.4 mg study group; −2.4% with placebo. |
| Glucagon-receptor activity | Included in its receptor profile.Glucagon-linked energy expenditure was demonstrated in the preclinical mouse study. | Not a target in its described receptor profile. | Not a target in its described receptor profile. |
| Development / authorised-product context | Investigational; Phase 3 TRIUMPH programme. | Approved prescription products exist, including Zepbound in the US. | Approved prescription products exist, including Wegovy in the US. |
How to read these figures. They are group averages from separate trials, not maximum possible results. An estimand defines how a treatment effect is calculated, including how discontinuation is handled. Study-group amounts identify the published evidence and are not dosing recommendations. Approval of a named prescription medicine does not extend to research products sold separately.
Study context & documentation
Different research settings answer different questions. Use the original publication and its methods to understand each study; clinical trial schedules are not instructions for using this research product.
Swipe horizontally to read the full reference.
| Research setting | Study timeframe | Reference & interpretation |
|---|---|---|
| In vitro receptor assays | Assay-specific | Examine receptor activity under defined laboratory conditions. Record the assay method, controls and batch documentation.Read the discovery study (opens in a new tab) |
| Phase 2 clinical study | 48 weeks | A controlled clinical trial with eligibility criteria, predefined treatment groups and safety monitoring. Its protocol does not establish a self-administration schedule.Read the Phase 2 publication (opens in a new tab) |
| Phase 3 TRIUMPH-1 | 80 weeks104-week extension in a prespecified subgroup | A separate investigational trial programme. Review the study population, endpoints and analysis before interpreting sponsor-reported findings.Read the trial announcement (opens in a new tab) |
For in vitro scientific research only. This product is not intended for human or animal consumption, or for therapeutic, diagnostic or cosmetic use. The 10 mg, 20 mg and 40 mg options indicate total vial content, not a weekly dose or treatment schedule.
Product specifications
Retatrutide supplied in a vial. Choose the total quantity contained in each vial: 10, 20 or 40 mg.
The certificate of analysis (COA) and HPLC data must match the batch you receive. Check their availability before ordering.
Target purity specification
Purity is no substitute for traceability. The batch certificate identifies the analytical method, results and laboratory. This document is required to verify compliance with the stated specification.
Good to know
Useful information to help you choose a format and review the documentation.
Research tools / Retatrutide
Choose a vial format and quantity to estimate total vial content and budget.
All prices are in AED.
Enter a whole number from 1 to 99.
Whole vials only. The quantity discounts shown on the product page apply automatically to each format.
Your estimate
Enter a valid vial quantity to see your estimate.
AED 39.90 per mg · Free delivery on 40 mg
Full price: no quantity discount for a single vial.
Estimates below use the same number of vials. Total vial content varies by format.
| Format | Total content | Subtotal | Price per mg |
|---|---|---|---|
| 10 mg vial | 10 mg | AED 399 | AED 39.90 |
| 20 mg vial | 20 mg | AED 599 | AED 29.95 |
| 40 mg vial | 40 mg | AED 999 | AED 24.98 |
Total content is the labelled amount per vial multiplied by the number of vials. It does not describe usable volume or a treatment duration.
The subtotal uses the same quantity discount as the product page and cart. Free delivery is included with the 40 mg format; other shipping costs are excluded.
Savings are the original total minus the discounted total for the same format. The unit price is rounded to two decimal places before multiplying by the quantity.